(AOF) – The French laboratory Biosynex, which designs, manufactures and distributes Rapid Diagnostic Tests (RDTs) has announced that it has taken a 75% stake in the capital of the Danish company Medkoncept, based in Hellerup, near Copenhagen. This company founded in 2017 and which has been the exclusive distributor in Denmark of rapid diagnostic tests related to Covid-19 will be renamed Biosynex Nordic after having marketed on behalf of Biosynex more than 26 million antigenic tests on the Danish market since 2021 .
With this acquisition, Biosynex intends to accelerate its penetration of the Nordic market, first in Denmark and Norway, then in Sweden and Finland from 2023, thanks to multiple synergy effects: Medkoncept’s solid distributor positions will serve in particular to widely distribute Biosynex’s product range: rapid diagnostic tests, Point of Care and molecular biology
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.